TLSA - Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology | Benzinga
NEW YORK, April 11, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough neuro-immunomodulation therapies, today announced an upcoming oral presentation, titled, "Treatment of PIRA with Nasal Foralumab Dampens Microglial Activation and Stabilizes Clinical Progression in Non-Active Secondary Progressive MS" that will be presented during the "Multiple Sclerosis: Therapeutics and Clinical Decision Making" session at the Annual Meeting of the American Academy of Neurology, to be held April 13-18, 2024 in Denver, Colorado.
Presentation Information:
| Presenter: |
| Tarun Singhal, M.B.B.S., M.D. (Associate Professor of Neurology, Harvard Medical School, and Associate Neurologist, Brigham and Women's Hospital, a founding member of Mass General Brigham Healthcare System) |